Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation

Journal of Cardiology

Volumn 42, Issue 3, 2003, Pages 111-117

  Komatsu, Takashi ^a,c   Yomogida, Kunihiko ^a   Nakamura, Shin ^a   Suzuki, Osamu ^a   Horiuchi, Daisuke ^a   Kameda, Kunihiko ^b   Tomita, Hirofumi ^b   Abe, Naoki ^b   Owada, Shingen ^b   Oikawa, Koichi ^b   Okumura, Ken ^b  

^a Iwate Prefectural Iwai Hospital   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Iwate Prefectural Iwai Hospital   (Japan)

Author keywords

Arrhythmias, treatment of; Atrial fibrillation; Drug therapy (disopyramide); Prevention

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRACTICE GUIDELINE; RECURRENT DISEASE; SINUS RHYTHM; TIME SERIES ANALYSIS; HEART ARRHYTHMIA; TIME;

AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; DISOPYRAMIDE; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RECURRENCE; TIME FACTORS;

EID: 0142010111     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibirllation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952
2. Middlekauff HR, Stevenson WG, Stevenson LW: Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients. Circulation 1991; 84: 40-48
3. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155: 469-473
4. Wijffels MCEF, Kirchhof CJHJ, Dorlald R, Allessie MA: Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968
5. Komatsu T, Nakamura S, Kimura M, Owada S, Saito E, Kobayashi T, Okumura K: Efficacy of cibenzoline in the termination and long-term prevention of paroxysmal atrial fibrillation: Analysis based on the time of onset. J Cardiol 2001; 37: 75-82 (in Jpn with Eng abstr)
6. Komatsu T, Nakamura S, Kimura M, Owada S, Tomita H, Yomogida K, Okumura K: Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: Analysis based on the time of onset. J Cardiol 2001; 38: 211-217 (in Jpn with Eng abstr)
7. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG: Management of patients with atrial fibrillation: A Statement for Healthcare Professionals: From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277
8. Allessie MA: Atrial electrophysiologic remodeling Another vicious circle? J Cardiovasc Electrophysiol 1998; 9: 1378-1393
9. Geotte A, Honeycutt C, Langberg JJ: Electrical remodeling in atrial fibrillation: Time course and mechanisms. Circulation 1996; 94: 2968-2974
10. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S: Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-525
11. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V: Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44: 121-131
12. + current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81: 1045-1052
13. van der Velden HMW, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allessie MA, Jongsma HJ: Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000; 46: 476-486
14. Elvan A, Huang XD, Pressler ML, Zipes DP: Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation 1997; 96: 1675-1685
15. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410
16. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE: Atrial enlargement as a consequence of atrial fibrillation: A prospective echocardiographic study. Circulation 1990; 82: 792-797
17. Stoddard MF, Dawkins PR, Prince CR, Ammash NM: Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardographic study. J Am Coll Cardiol 1995; 25: 452-459
18. Chimowitz MI, DeGeorgia MA, Poole RM, Hepner A, Armstrong WM: Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke 1993; 24: 1015-1019
19. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS: Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25: 1354-1361
20. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851
21. Komatsu T, Nakamura S, Yomogida K, Kimura M, Owada S, Okumura K: Early defibrillation increase the subsequent long-term effect of cibenzoline in patients with symptomatic atrial fibrillation. Circ J 2002; 66(Suppl): 346 (abstr)
22. Ganz LI, Antman EM: Antiarrhythmic drug therapy in the management of atrial fibrillation. J Cardiovasc Electrophysiol 1997; 8: 1175-1189
23. Madrid AH, Bueno MG, Rebollo JMG, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336
24. Prichett ELC, DaTorre SD, Platt ML, McCarville SE, Hougham AJ, for the Flecainide Supraventricular Tachycardia Study Group: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies. J Am Coll Cardiol 1991; 17: 297-303
25. Lau CP, Leung WH, Wong CK: A ramdomized double-blind crossover study comparing the efficacy and tolerability of flecainide and qunidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992; 124: 645-650
26. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC, the Flecainide Supraventricular Tachycardia Study Group: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557-1570
27. UK Propafenone PSVT Study Group: A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550-2557
28. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL: Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-227